Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Journal of Infection

Volumn 67, Issue 6, 2013, Pages 606-616

  Chan, Jasper F W ^a,b   Chan, Kwok Hung ^b   Kao, Richard Y T ^a,b   To, Kelvin K W ^a,b   Zheng, Bo Jian ^a,b   Li, Clara P Y ^b   Li, Patrick T W ^b   Dai, Jun ^b   Mok, Florence K Y ^b   Chen, Honglin ^a,b   Hayden, Frederick G ^c   Yuen, Kwok Yung ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antiviral; Coronavirus; Interferon; Middle East; Mycophenolic acid; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; BETA1A INTERFERON; GAMMA1B INTERFERON; INTERFERON; INTERFERON BETA SERINE; LOPINAVIR; MYCOPHENOLIC ACID; NELFINAVIR; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL GENETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS; CYTOPATHOGENIC EFFECT; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INFLUENZA VIRUS A; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; VIRUS INHIBITION; VIRUS PLAQUE;

ANTIVIRAL; CORONAVIRUS; INTERFERON; MIDDLE EAST; MYCOPHENOLIC ACID; RIBAVIRIN;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERFERONS; MYCOPHENOLIC ACID; RIBAVIRIN; VERO CELLS; VIRAL LOAD; VIRAL PLAQUE ASSAY;

EID: 84887019388     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.029     Document Type: Article

References (73)

1. Chan J.F., Li K.S., To K.K., Cheng V.C., Chen H., Yuen K.Y. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J Infect 2012, 65:477-489.
2. Chan J.F., Lau S.K., Woo P.C. The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". J Formos Med Assoc 2013, 112:372-381.
3. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
4. de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV); announcement of the coronavirus study group. J Virol 2013, 87:7790-7792.
5. World Health Organization Global alert and response: Middle East respiratory syndrome coronavirus (MERS-CoV) - update - as of 4 October 2013 2013, WHO, Geneva, [accessed 05.10.13]. http://www.who.int/csr/don/2013_10_04/en/index.html.
6. Woo P.C., Wang M., Lau S.K., Xu H., Poon R.W., Guo R., et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol 2007, 81:1574-1585.
7. Woo P.C., Lau S.K., Li K.S., Tsang A.K., Yuen K.Y. Genetic relatedness of the novel human lineage C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg Microbe Infect 2012, 1:e35. 10.1038/emi.2012.45.
8. Lau S.K., Li K.S., Tsang A.K., Lam C.S., Ahmed S., Chen H., et al. Genetic characterization of Betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications on the origin of the novel Middle East Respiratory Syndrome Coronavirus. J Virol 2013, 87:8638-8650.
9. Chan J.F., To K.K., Tse H., Jin D.Y., Yuen K.Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013, 21:544-555.
10. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3. pii: e00473-12.
11. Annan A., Baldwin H.J., Corman V.M., Klose S.M., Owusu M., Nkrumah E.E., et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013, 19:456-459.
12. Anthony S.J., Ojeda-Flores R., Rico-Chávez O., Navarrete-Macias I., Zambrana-Torrelio C.M., Rostal M.K., et al. Coronaviruses in bats from Mexico. J Gen Virol 2013, 94:1028-1038.
13. Lu L., Liu Q., Du L., Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013, 15:625-629.
14. Chan J.F., Chan K.H., Choi G.K., To K.K., Tse H., Cai J.P., et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications on disease pathogenesis and clinical manifestation. J Infect Dis 2013, 207:1743-1752.
15. Müller M.A., Raj V.S., Muth D., Meyer B., Kallies S., Smits S.L., et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012, 3. pii: e00515-12.
16. Reusken C.B., Haagmans B.L., Müller M.A., Gutierrez C., Meyer B., Muth B., et al. Middle East respiratory syndrome coronavirus neutralizing serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013, 13:859-866.
17. Centers for Disease Control and Prevention (CDC) Update: severe respiratory illness associated with middle East respiratory syndrome coronavirus (MERS-CoV) - Worldwide, 2012-2013. MMWR Morb Mortal Wkly Rep 2013, 62:480-483.
18. Guery B., Poissy J., El Mansouf L., Séjoruné C., Ettahar N., Lemaire X., et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013, 381:2265-2272.
19. Memish Z.A., Zumla Al, Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of middle East respiratory syndrome coronavirus infections. N Engl J Med 2013, 369:587.
20. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A., et al. Hospital outbreak of middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
21. Omrani A.S., Matin M.A., Haddad Q., Al-Nakhli D., Memish Z.A., Albarrak A.M. A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013, 17:e668-e672.
22. Mailles A., Blanckaert K., Chaud P., van der Werf S., Lina B., Caro V., et al. First cases of middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013, 18. pii: 20502.
23. Drosten C., Seilmaier M., Corman V.M., Hartmann W., Scheible G., Sack S., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, 13:745-751.
24. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
25. Kao R.Y., Yang D., Lau L.S., Tsui W.H., Hu L., Dai J., et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010, 28:600-605.
26. Cheng V.C., To K.K., Tse H., Hung I.F., Yuen K.Y. Two years after pandemic influenza A/2009/H1N1: what have we learned?. Clin Microbiol Rev 2012, 25:223-263.
27. To K.K., Ng K.H., Que T.L., Chan J.M., Tsang K.Y., Tsang A.K., et al. Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 2012, 1:e25.
28. Chen Y., Liang W., Yang S., Wu N., Gao H., Sheng J., et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013, 381:1916-1925.
29. To K.K., Chan J.F., Chen H., Li L., Yuen K.Y. The emergence of influenza A (H7N9) sixteen years after influenza A(H5N1) in humans: a tale of two cities. Lancet Infect Dis 2013, 13:809-821.
30. Yu L., Wang Z., Chen Y., Ding W., Jia H., Chan J.F., et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 2013, [Epub ahead of print].
31. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008, 105:8091-8096.
32. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004, 59:252-256.
33. Chou C.Y., Chien C.H., Han Y.S., Prebanda M.T., Hsieh H.P., Turk B., et al. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol 2008, 75:1601-1609.
34. Cheng V.C., Lau S.K., Woo P.C., Yuen K.Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007, 20:660-694.
35. Chen F., Chan K.H., Jiang Y., Kao R.Y., Lu H.T., Fan K.W., et al. Invitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004, 31:69-75.
36. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet 2003, 362:392-394.
37. de Lang A., Osterhaus A.D., Haggmans B.L. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006, 353:474-481.
38. Kao R.Y., To A.P., Ng L.W., Tsui W.H., Lee T.S., Tsoi H.W., et al. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Lett 2004, 576:325-330.
39. Kao R.Y., Tsui W.H., Lee T.S., Tanner J.A., Watt R.M., Huang J.D., et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 2004, 11:1293-1299.
40. Falzarano D., de Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013, 3:1686.
41. Villarroel M.C., Hidalgo M., Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc) 2009, 45:521-532.
42. Morrey J.D., Smee D.F., Sidwell R.W., Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002, 55:107-116.
43. Sebastian L., Madhusudana S.N., Ravi V., Desai A. Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 2011, 57:56-61.
44. Leyssen P., Balzarini J., De Clercq E., Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity invitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005, 79:1943-1947.
45. Diamond M.S., Zachariah M., Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 2002, 304:211-221.
46. Khan M., Dhanwani R., Patro I.K., Rao P.V., Parida M.M. Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 2011, 89:1-8.
47. Pan Q., van Vuuren A.J., van der Laan L.J., Peppelenbosch M.P., Janssen H.L. Antiviral or proviral action of mycophenolic acid in hepatitis B infection?. Hepatology 2012, 56:1586-1587.
48. Pan Q., de Ruiter P.E., Metselaar H.J., Kwekkeboom J., de Jonge J., Tilanus H.W., et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection invitro and invivo. Hepatology 2012, 55:1673-1683.
49. Ye L., Li J., Zhang T., Wang X., Wang Y., Zhou Y., et al. Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res 2012, 168:33-40.
50. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res 2006, 71:53-63.
51. Wong S.S., Yuen K.Y. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008, 62:437-441.
52. Cheng V.C., Tang B.S., Wu Ak, Chu C.M., Yuen K.Y. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect 2004, 49:262-273.
53. de Wilde A.H., Ray V.S., Oudshoorn D., Besterbroer T.M., van Nieuwkoop S., Limpens R.W., et al. MERS-coronavirus replication induces severe invitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013, 94:1749-1760.
54. S.K.A.Lau, Lau C.C., Chan K.H., Li C.P., Chen H., Jin D.Y., et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013, [Epub ahead of print].
55. J.B.Zhou, Chu H., Li C., Wong B.H., Cheng Z.S., Poon V.K., et al. Active MERS-CoV replication and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2013, [Epub ahead of print].
56. Product Information: Betaferon® Single use pack drug (AUST R 83309). [accessed 18.06.13]. http://www.bayerresources.com.au/resources/uploads/PI/file9314.pdf.
57. Johnston A., He X., Holt D.W. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006, 82:1413-1418.
58. Koren G., King S., Knowles S., Phillips E. Ribavirin in the treatment of SARS: a new trick for an old bug?. CMAJ 2003, 168:1289-1292.
59. Brochot E., Castelain S., Duverlie G., Capron D., Nguyen-Khac E., François C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antiviral Ther 2010, 15:687-695.
60. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118.
61. Hayden F.G., Cote K.M., Douglas R.G. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980, 17:865-870.
62. Hayden F.G., Douglas R.G., Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980, 18:536-541.
63. Shah N.R., Sunderland A., Grdzelishvili V.Z. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One 2010, 5:e11265.
64. Adedeji A.O., Singh K., Calcaterra N.E., DeDiego M.L., Enjuanes L., Weiss S., et al. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother 2012, 56:4718-4728.
65. Chen L., Liu P., Gao H., Sun B., Chao D., Wang F., et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004, 39:1531-1535.
66. Akerström S., Mousavi-Jazi M., Klingström J., Leijon M., Lundkvist A., Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005, 79:1966-1969.
67. Chan K.H., Chan J.F., Tse H., Chen H., Lau C.C., Cai J.P. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013, 67:130-140.
68. Jiang S, Lu L, Du L, Debnath AK. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect 66: 464-6.
69. Du L., Zhao G., Kou Z., Ma C., Sun S., Poon V.K., et al. Identification of a receptor-binding domain in the s protine of the novel human coronavirus middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013, 87:9939-9942.
70. Zheng B.J., Guan Y., Hez M.L., Sun H., Du L., Zheng Y., et al. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir Ther 2005, 10:393-403.
71. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Müller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
72. Tanaka Y., Sato Y., Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses 2013, 5:1250-1260.
73. Munster V.J., de Wit E., Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med 2013, 368:1560-1562.